Do tissue plasminogen activator-plasminogen activator inhibitor-1 complexes relate to the complications of insulin-dependent diabetes mellitus? Pittsburgh Epidemiology of Diabetes Complications study

Journal of Diabetes and its Complications

Volumn 11, Issue 4, 1997, Pages 243-249

  Maser, Raelene E ^a   Ellis, Demetrius ^b   Erbey, John R ^c   Orchard, Trevor J ^c  

^a UNIVERSITY OF DELAWARE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; DATA ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; FIBRINOLYSIS; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGING; ALBUMINURIA; BLOOD PRESSURE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 0030953072     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(96)00040-2     Document Type: Article

References (30)

1. Schrauwen Y, Emeis JJ, Kooistra T: A sensitive ELISA for human tissue-type plasminogen activator applicable to the study of acute release from cultured human endothelial cells. Thromb Haemost 71:225-229, 1994.
2. Amiral J, Plassart V, Grosley M, Mimilla F, Contant G, Guyader AM: Measurement of tPA and tPA-PAI-1 complexes by ELISA using monoclonal antibodies: clinical relevance. Thromb Res (suppl VIII):99-113, 1988.
3. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:1116-1124, 1990.
4. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Ellis D, LaPorte RE, Kuller LH, Wolfson SK, Drash AL: Factors associated with avoidance of severe complications after 25 yr of IDDM. Pittsburgh Epidemiology of Diabetes Complications Study I. Diabetes Care 13:741-747, 1990.
5. Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J: The hypertension detection and follow-up program. Prev Med 5:207-215, 1976.
6. Orchard TJ for the CCSP Investigators: Validation of coronary heart disease mortality data: the Community Cardiovascular Surveillance Project Pilot Experience. Am Heart Assoc Cardiovasc Dis Epidemiol Newslett 157:46, 1985.
7. Fujii S, Sawa H, Sobel DE: Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by Gemfibrozil. Thromb Haemost 70:642-647, 1993.
8. Huber K, Beckmann R, Lang I, Schuster E, Binder BR: Circadian fluctuations in plasma levels of tissue plasminogen activator antigen and plasminogen activator inhibitor activity. Fibrinolysis 3:41-43, 1989.
9. Takada Y, Urano T, Watanabe I, Taminato A, Yoshimi T, Takada A: Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 71:405-415, 1993.
10. Phillips DK: Hypercoagulability and thrombosis: The promise of endothelial cells. Clin Lab Sci 3:170, 1990.
11. Kostraba JN, Klein R, Dorman JS, Becker DJ, Drash AL, Maser RE, Orchard TJ: The Epidemiology of Diabetes Complications Study. IV. Correlates of diabetic background and proliferative retinopathy. Am J Epidemiol 133:381-391, 1991.
12. Kannel WD, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease: The Framingham Study. JAMA 258:1183-1186, 1987.
13. Ganda OP: Markedly increased erythrocyte sedimentation rate, hyperfibrinogenemia, and peripheral vascular disease in diabetic patients: Association with clinical implications. Am J Med 85:584-585, 1988.
14. Jones SL, Close CF, Mattock MD, Jarrett RJ, Keen H, Viberti GC: Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ 298:487-490, 1989.
15. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, Drash AL, Becker DJ, Kuller LH, Greene DA, Orchard TJ: Epidemiological Correlates of Diabetic Neuropathy. Report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 38:1456-1461, 1989.
16. Ahmad M, Saku K, Glas-Greenwalt P, Kashyap ML: Inhibitor and activator of plasminogen in patients with hyperlipoproteinemias [Abstract]. Thromb Haemost 54: 266, 1985.
17. Crutchley DJ, McPhee GV, Terris MF, Canossa-Terris MA: Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis 9:934-939, 1989.
18. Maiello M, Boeri D, Podesta F, Cagliero E, Vichi M, Odetti P, Adezati L, Lorenzi M: Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 41:1009-1015, 1992.
19. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, Mariani G: Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 67:643-654, 1992.
20. Ross, R: The pathogenesis of atherosclerosis: an update. N Engl J Med 314:488-500, 1986.
21. Lorenzi M, Nordberg JA, Toledo S: High glucose prolongs cell-cycle traversal of cultured human endothelial cells. Diabetes 36:1261-1267, 1987.
22. Williams JK, Adams MR, Klopfenstein HS: Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 81:1680-1687, 1990.
23. Yamauchi K, Suzuki T, Furumichi T, Saito H: Plasma tPA/PAI-1 complex and blood coagulability in patients with coronary artery disease. Jpn Heart J 33:351-358, 1992.
24. Gray RP, Patterson DLH, Yudkin JS: Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb 13:415-420, 1993.
25. Aimer L, Sundkvist G, Lilja B: Fibrinolytic activity, autonomic neuropathy, and circulation in diabetes mellitus. Diabetes 32 (suppl 2):4-7, 1983.
26. Lijnen HR, Collen D: Congenital and acquired deficiencies of components of the fibrinolytic system and their relation to bleeding or thrombosis. Fibrinolysis 3:67-77, 1989.
27. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P: Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients: Relationship with plasma insulin. Thromb Haemost 61:370-373, 1989.
28. Mahmoud R, Raccah D, Alessi MC, Aillaud MF, Juhan-Vague I, Vague P. Fibrinolysis in insulin-dependent diabetic patients with or without nephropathy. Fibrinolysis 6:105-109, 1992.
29. Vague P. Insulin and the fibrinolytic system: A link between metabolism and thrombogenesis. IDF Bull 36: 15-17, 1991.
30. Stuhldreher WL, Orchard TJ, Ellis D: The association of waist-hip ratio and risk factors for development of IDDM complications in an IDDM adult population. Diabetes Res Clin Pract 17:99-109, 1992.